Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Improving Immunotherapy for Lung Cancer Using Double-Negative T-Cells in Combination with Hypoxia-Reducing Manganese Dioxide Nanoparticles
FY 2018-19
Summary
Lung cancer is the leading cause of all cancer-related deaths, with current therapies often ineffective. Recently, immunotherapy has emerged as a promising approach that utilizes the host immune system to fight cancer, but only a subset of patients are responsive. As a result, better treatments are urgently required. Discovered by our lab, double-negative T-cells (DNTs) are a distinct subset of mature T-cells that express CD3 in the absence of CD4 and CD8. They possess advantages such as the ability to inhibit the growth of established lung cancer tumors and acute myeloid leukemia without attacking normal cells. They also have the potential to be a safe and feasible off-the-shelf immunotherapy. Nonetheless, like other T-cell immunotherapies, DNTs are limited by the immunosuppressive tumor microenvironment (TME) of solid tumors such as lung cancer. A key TME feature and barrier to treating solid tumors is hypoxia, a deficiency of oxygen in the tumor. It is a negative prognostic marker predicting poor survival and outcome in patients. Hypoxia inhibits T-cell function and tumor infiltration, while inducing T-cell death and exhaustion to suppress antitumor responses. Consequently, the purpose of my project is to investigate a novel combination therapy between DNTs and biocompatible hybrid manganese dioxide nanoparticles (LMD NPs) that reduce hypoxia. The effects of LMD NPs on the hypoxic TME, the mechanism by which TME modulations by NPs may improve DNT aspects such as function and infiltration, and the efficacy of the combination therapy in murine lung cancer models will be examined. In combining LMD NPs with DNTs, typical barriers prevalent in immunotherapy and the hostile TME of solid tumors may be overcome to further enhance the unique cellular therapy provided by DNTs.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406526
Name
Leung Yuki S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Improving Immunotherapy for Lung Cancer Using Double-Negative T-Cells in Combination with Hypoxia-Reducing Manganese Dioxide Nanoparticles
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cellular Therapy; Combination Therapy; Double-Negative T-Cells; Hypoxia; Immunosuppression; Immunotherapy; Lung Cancer; Nanoparticles; Solid Tumor; Tumor Microenvironment
Abstract
Lung cancer is the leading cause of all cancer-related deaths, with current therapies often ineffective. Recently, immunotherapy has emerged as a promising approach that utilizes the host immune system to fight cancer, but only a subset of patients are responsive. As a result, better treatments are urgently required. Discovered by our lab, double-negative T-cells (DNTs) are a distinct subset of mature T-cells that express CD3 in the absence of CD4 and CD8. They possess advantages such as the ability to inhibit the growth of established lung cancer tumors and acute myeloid leukemia without attacking normal cells. They also have the potential to be a safe and feasible off-the-shelf immunotherapy. Nonetheless, like other T-cell immunotherapies, DNTs are limited by the immunosuppressive tumor microenvironment (TME) of solid tumors such as lung cancer. A key TME feature and barrier to treating solid tumors is hypoxia, a deficiency of oxygen in the tumor. It is a negative prognostic marker predicting poor survival and outcome in patients. Hypoxia inhibits T-cell function and tumor infiltration, while inducing T-cell death and exhaustion to suppress antitumor responses. Consequently, the purpose of my project is to investigate a novel combination therapy between DNTs and biocompatible hybrid manganese dioxide nanoparticles (LMD NPs) that reduce hypoxia. The effects of LMD NPs on the hypoxic TME, the mechanism by which TME modulations by NPs may improve DNT aspects such as function and infiltration, and the efficacy of the combination therapy in murine lung cancer models will be examined. In combining LMD NPs with DNTs, typical barriers prevalent in immunotherapy and the hostile TME of solid tumors may be overcome to further enhance the unique cellular therapy provided by DNTs.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leung, Yuki S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~